Analysis of the Rembrandt database revealed that the overall survival of patients with glioma (WHO grades II–IV) with a more than 2-fold increase of GCS was significantly reduced and with a more than 2-fold decrease of GCS significantly prolonged in comparison with patients with intermediate expression of this gene (Fig. 1F). The gene discussed is UGCG; the disease is glioma.